Abstract

BackgroundMolecular and epidemiological evidence demonstrate that altered gene expression and single nucleotide polymorphisms in the apoptotic pathway are linked to many cancers. Yet, few studies emphasize the interaction of variant apoptotic genes and their joint modifying effects on prostate cancer (PCA) outcomes. An exhaustive assessment of all the possible two-, three- and four-way gene-gene interactions is computationally burdensome. This statistical conundrum stems from the prohibitive amount of data needed to account for multiple hypothesis testing.MethodsTo address this issue, we systematically prioritized and evaluated individual effects and complex interactions among 172 apoptotic SNPs in relation to PCA risk and aggressive disease (i.e., Gleason score ≥ 7 and tumor stages III/IV). Single and joint modifying effects on PCA outcomes among European-American men were analyzed using statistical epistasis networks coupled with multi-factor dimensionality reduction (SEN-guided MDR). The case-control study design included 1,175 incident PCA cases and 1,111 controls from the prostate, lung, colo-rectal, and ovarian (PLCO) cancer screening trial. Moreover, a subset analysis of PCA cases consisted of 688 aggressive and 488 non-aggressive PCA cases. SNP profiles were obtained using the NCI Cancer Genetic Markers of Susceptibility (CGEMS) data portal. Main effects were assessed using logistic regression (LR) models. Prior to modeling interactions, SEN was used to pre-process our genetic data. SEN used network science to reduce our analysis from > 36 million to < 13,000 SNP interactions. Interactions were visualized, evaluated, and validated using entropy-based MDR. All parametric and non-parametric models were adjusted for age, family history of PCA, and multiple hypothesis testing.ResultsFollowing LR modeling, eleven and thirteen sequence variants were associated with PCA risk and aggressive disease, respectively. However, none of these markers remained significant after we adjusted for multiple comparisons. Nevertheless, we detected a modest synergistic interaction between AKT3 rs2125230-PRKCQ rs571715 and disease aggressiveness using SEN-guided MDR (p = 0.011).ConclusionsIn summary, entropy-based SEN-guided MDR facilitated the logical prioritization and evaluation of apoptotic SNPs in relation to aggressive PCA. The suggestive interaction between AKT3-PRKCQ and aggressive PCA requires further validation using independent observational studies.

Highlights

  • Molecular and epidemiological evidence demonstrate that altered gene expression and single nucleotide polymorphisms in the apoptotic pathway are linked to many cancers

  • Several independent studies have shown that overexpression of cell survival indicators (e.g., BCL-2, CARD8, IKBKE, PRKCQ, and PIK3CB, AKT3) or down-regulation of cell death markers (e.g., B-cell CL/lymphoma 2 (BCL2)-like 14 (BCL2L14)) are associated with more aggressive phenotypes, higher Gleason grade, increased tumor progression, and poor prostate cancer (PCA) prognosis [6,7,8,9,10,11,12,13,14,15,16,17,18,19]

  • Cancer Genetic Markers of Susceptibility (CGEMS) Population Description CGEMS study participants consisted of middle aged nonHispanic Caucasian men, ranging in age from 55 to 81

Read more

Summary

Introduction

Molecular and epidemiological evidence demonstrate that altered gene expression and single nucleotide polymorphisms in the apoptotic pathway are linked to many cancers. Apoptosis or programmed cell death is one such biological process that moderates cell differentiation, proliferation, death, whole body homeostasis and tumorigenesis [2,3,4]. Several independent studies have shown that overexpression of cell survival indicators (e.g., BCL-2, CARD8, IKBKE, PRKCQ, and PIK3CB, AKT3) or down-regulation of cell death markers (e.g., BCL2L14) are associated with more aggressive phenotypes, higher Gleason grade, increased tumor progression, and poor PCA prognosis [6,7,8,9,10,11,12,13,14,15,16,17,18,19]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.